These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23754289)

  • 1. Molecular basis for benzodiazepine agonist action at the type 1 cholecystokinin receptor.
    Harikumar KG; Cawston EE; Lam PCH; Patil A; Orry A; Henke BR; Abagyan R; Christopoulos A; Sexton PM; Miller LJ
    J Biol Chem; 2013 Jul; 288(29):21082-21095. PubMed ID: 23754289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.
    Desai AJ; Lam PC; Orry A; Abagyan R; Christopoulos A; Sexton PM; Miller LJ
    J Med Chem; 2015 Dec; 58(24):9562-77. PubMed ID: 26654202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor.
    Hadac EM; Dawson ES; Darrow JW; Sugg EE; Lybrand TP; Miller LJ
    J Med Chem; 2006 Feb; 49(3):850-63. PubMed ID: 16451051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors.
    Akgün E; Körner M; Gao F; Harikumar KG; Waser B; Reubi JC; Portoghese PS; Miller LJ
    J Med Chem; 2009 Apr; 52(7):2138-47. PubMed ID: 19271701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding.
    Dong M; Vattelana AM; Lam PC; Orry AJ; Abagyan R; Christopoulos A; Sexton PM; Haines DR; Miller LJ
    Mol Pharmacol; 2015 Jan; 87(1):130-40. PubMed ID: 25319540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A type 1 cholecystokinin receptor mutant that mimics the dysfunction observed for wild type receptor in a high cholesterol environment.
    Desai AJ; Harikumar KG; Miller LJ
    J Biol Chem; 2014 Jun; 289(26):18314-26. PubMed ID: 24825903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling.
    Dong M; Liu G; Pinon DI; Miller LJ
    Biochemistry; 2005 May; 44(17):6693-700. PubMed ID: 15850403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elimination of a cholecystokinin receptor agonist 'trigger' in an effort to develop positive allosteric modulators without intrinsic agonist activity.
    Desai AJ; Henke BR; Miller LJ
    Bioorg Med Chem Lett; 2015 May; 25(9):1849-55. PubMed ID: 25862198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular basis for binding and subtype selectivity of 1,4-benzodiazepine antagonist ligands of the cholecystokinin receptor.
    Cawston EE; Lam PC; Harikumar KG; Dong M; Ball AM; Augustine ML; Akgün E; Portoghese PS; Orry A; Abagyan R; Sexton PM; Miller LJ
    J Biol Chem; 2012 May; 287(22):18618-35. PubMed ID: 22467877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide/benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors.
    Escherich A; Lutz J; Escrieut C; Fourmy D; van Neuren AS; Müller G; Schafferhans A; Klebe G; Moroder L
    Biopolymers; 2000-2001; 56(2):55-76. PubMed ID: 11592053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benzodiazepine ligands can act as allosteric modulators of the Type 1 cholecystokinin receptor.
    Gao F; Sexton PM; Christopoulos A; Miller LJ
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4401-4. PubMed ID: 18621527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescence polarization screening for allosteric small molecule ligands of the cholecystokinin receptor.
    Harikumar KG; Cawston EE; Miller LJ
    Assay Drug Dev Technol; 2011 Aug; 9(4):394-402. PubMed ID: 21395402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger".
    Aquino CJ; Armour DR; Berman JM; Birkemo LS; Carr RA; Croom DK; Dezube M; Dougherty RW; Ervin GN; Grizzle MK; Head JE; Hirst GC; James MK; Johnson MF; Miller LJ; Queen KL; Rimele TJ; Smith DN; Sugg EE
    J Med Chem; 1996 Jan; 39(2):562-9. PubMed ID: 8558528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist.
    Arlander SJ; Dong M; Ding XQ; Pinon DI; Miller LJ
    Mol Pharmacol; 2004 Sep; 66(3):545-52. PubMed ID: 15322246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterodimerization of type A and B cholecystokinin receptors enhance signaling and promote cell growth.
    Cheng ZJ; Harikumar KG; Holicky EL; Miller LJ
    J Biol Chem; 2003 Dec; 278(52):52972-9. PubMed ID: 14534299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligand-induced internalization of the type 1 cholecystokinin receptor independent of recognized signaling activity.
    Cawston EE; Harikumar KG; Miller LJ
    Am J Physiol Cell Physiol; 2012 Feb; 302(3):C615-27. PubMed ID: 22049215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel, achiral 1,3,4-benzotriazepine analogues of 1,4-benzodiazepine-based CCK(2) antagonists that display high selectivity over CCK(1) receptors.
    McDonald IM; Austin C; Buck IM; Dunstone DJ; Griffin E; Harper EA; Hull RA; Kalindjian SB; Linney ID; Low CM; Pether MJ; Spencer J; Wright PT; Adatia T; Bashall A
    J Med Chem; 2006 Apr; 49(7):2253-61. PubMed ID: 16570921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists.
    Henke BR; Aquino CJ; Birkemo LS; Croom DK; Dougherty RW; Ervin GN; Grizzle MK; Hirst GC; James MK; Johnson MF; Queen KL; Sherrill RG; Sugg EE; Suh EM; Szewczyk JW; Unwalla RJ; Yingling J; Willson TM
    J Med Chem; 1997 Aug; 40(17):2706-25. PubMed ID: 9276016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amino substituent.
    Hirst GC; Aquino C; Birkemo L; Croom DK; Dezube M; Dougherty RW; Ervin GN; Grizzle MK; Henke B; James MK; Johnson MF; Momtahen T; Queen KL; Sherrill RG; Szewczyk J; Willson TM; Sugg EE
    J Med Chem; 1996 Dec; 39(26):5236-45. PubMed ID: 8978852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescent indicators distributed throughout the pharmacophore of cholecystokinin provide insights into distinct modes of binding and activation of type A and B cholecystokinin receptors.
    Harikumar KG; Pinon DI; Miller LJ
    J Biol Chem; 2006 Sep; 281(37):27072-80. PubMed ID: 16857665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.